Document is current
Any future updates will be listed below
-
Authors
van Vloten, Jacob P
Matuszewska, Kathy
Minow, Mark A A
Minott, Jessica A
Santry, Lisa A
Pereira, Madison
Stegelmeier, Ashley A
McAusland, Thomas M
Klafuric, Elaine M
Karimi, Khalil
Colasanti, Joseph
McFadden, D Grant
Petrik, James J
Bridle, Byram W
Wootton, Sarah K https://orcid.org/0000-0002-5985-2406
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00408590 at ClinicalTrials.govnct01274624 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
https://doi.org/10.1136/jitc-2021-004335
nct03663712 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
https://doi.org/10.1136/jitc-2021-004335
nct00964756 at ClinicalTrials.govDocuments that mention this clinical trial
409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)
https://doi.org/10.1136/jitc-2020-sitc2020.0409
Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).
https://doi.org/10.1200/jco.2024.42.16_suppl.2668
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
https://doi.org/10.1136/jitc-2021-004335
nct02759588 at ClinicalTrials.govDocuments that mention this clinical trial
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
https://doi.org/10.1136/jitc-2021-004335
Documents that mention this clinical trial
120 Factors associated with extended survival for patients with platinum-resistant ovarian cancer (PROC) treated with modified vaccinia oncolytic virotherapy (VOV)
https://doi.org/10.1136/ijgc-2019-igcs.120
12 Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant/refractory ovarian cancer
https://doi.org/10.1136/ijgc-2020-igcs.12
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
https://doi.org/10.1136/jitc-2021-004335
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
-
Funding
Funding for this research was provided by:
Natural Sciences and Engineering Research Council
Cancer Research Society
Ontario Veterinary College
Terry Fox Research Institute
Ontario Graduate Scholarship, Ontario Ministry of Agriculture and Rural Affairs Highly Qualified
Skies Cancer Fund and the Pet Trust Foundation
Science Without Borders Program
NSERC (436264)
NSERC (499834)
Natural Sciences and Engineering Research Council of Canada
- License Information
